A Review of Research Conducted with Probiotic E. coli Marketed as Symbioflor
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
This review article summarizes the scientific literature that is currently available about a probiotic E. coli that is known under the name Symbioflor E. coli. The probiotic is marketed for human use and has been subjected to over 20 years of scientific research. As is presented here, the available literature not only contains multiple works to investigate and analyse the probiotic activity of this E. coli, but also describes a variety of other research experiments, dealing with a surprising and interesting range of subjects. By compiling all these works into one review article, more insights into this interesting probiotic E. coli were obtained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Escherichia coli Nissle 1917 (EcN) has been used as a probiotic since its isolation over 100 years ago21.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacteriocins—A viable alternative to antibiotics?
Cotter, P. D., Ross, R. P., & Hill, C. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2937 · Cited by 1,793
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Didari, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i10.3072 · Cited by 356
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212
Möndel, M., Schroeder, B. O., Zimmermann, K., Huber, H., Nuding, S., Beisner, J., Fellermann, K., Stange, E. F., & Wehkamp, J. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.77 · Cited by 157
Enck, P., Zimmermann, K., Menke, G., Müller‐lissner, S., Martens, U., & Klosterhalfen, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01156.x · Cited by 123 · cited 1×
“This resulted in an analysis where the 264 patients of Enck et al. 2008 and the 298 patients from Enck et al. 2009 were combined [35], ignoring the fact that in the latter trial Symbioflor was used while in the first ProSymbioflor had been applied (the bacterial lysate).”
MethodEnck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027702 · Cited by 100
Escherichia coli Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium
Jacobi, C. A., & Malfertheiner, P. (2011) · Digestive Diseases · doi:10.1159/000333307 · Cited by 95 · cited 1×
“The properties of that strain have been reviewed elsewhere [1], but here all peer-reviewed publications dealing”
BackgroundCharacterization of probiotic Escherichia coliisolates with a novel pan-genome microarray
Willenbrock, H., Hallin, P. F., Wassenaar, T. M., & Ussery, D. W. (2007) · Genome Biology · doi:10.1186/gb-2007-8-12-r267 · Cited by 94 · cited 2×
“A core genome of 3083 genes was identified that all four genotypes shared [11].”
BackgroundZschüttig, A., Zimmermann, K., Blom, J., Goesmann, A., Pöhlmann, C., & Gunzer, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033351 · Cited by 81
Cited by
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H. M., Nomburg, J., Gurjao, C., Manders, F., Dalmasso, G., Stege, P. B., et al. (2020) · Nature · doi:10.1038/s41586-020-2080-8 · Cited by 1,208
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Postbiotics and paraprobiotics: From concepts to applications
Cuevas-González, P. F., Liceaga, A. M., & Aguilar-Toalá, J. E. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109502 · Cited by 431
The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties
Maftei, N.-M., Raileanu, C. R., Balta, A. A., Ambrose, L., Boev, M., Marin, D. B., & Lisa, E. L. (2024) · Microorganisms · doi:10.3390/microorganisms12020234 · Cited by 381
“[77–79] The number of probiotics is measured in colony-forming units (CFUs), which indicates the number of viable cells—for example, 1 × 10 9 or 1 billion CFU and 1 × 10 10 or 10 billion CFU).”
MethodGut microbiota as a source of novel antimicrobials
Garcia-Gutierrez, E., Mayer, M. J., Cotter, P. D., & Narbad, A. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1455790 · Cited by 292
“coli genotypes, and used for gastrointestinal disorder treatments, especially intestinal bowel syndrome (IBS).(136) Microcin S inhibits the adhesion of the enteropathogenic E.”
Recent Advances in Understanding the Structure and Function of the Human Microbiome
Mousa, W. K., Chehadeh, F., & Husband, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.825338 · Cited by 99
“Bulgaricus, and L. delbrueckii subsp. lactis Toba et al., 1991 IId peptides Microcin S E. coli G3/10 E. coli G3/10 Beimfohr, 2016 Rhamnosin A Lactobacillus rhamnosus strain 68 Micrococcus lysodeikticus ATCC 4698 Dimitrijević et al., 2009 Bacteriolysin Colicins E. coli Enterobacteria Salomón and Farías, 1992 Non-lytic…”
BackgroundMetabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors
Chiang, C., & Huang, P.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-85372-6 · Cited by 59
Genetically engineered bacteria: a new frontier in targeted drug delivery
Fooladi, S., Rabiee, N., & Iravani, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01805a · Cited by 53
In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy
Chiang, C., & Hong, Y.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-97457-3 · Cited by 47
Perreault, M., Means, J., Gerson, E., James, M., Cotton, S. L., Bergeron, C. G., Simon, M. D., Carlin, D. A., Schmidt, N., Moore, T. C., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.005 · Cited by 39
Escherichia coli - Old and New Insights
Erjavec, M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95203 · Cited by 25
Human microbiota peptides: important roles in human health
Shah, A. B., & Shim, S. H. (2025) · Natural Product Reports · doi:10.1039/d4np00042k · Cited by 26
Enumeration of Escherichia coli in Probiotic Products
Zimmer, C., & Dorea, C. C. (2019) · Microorganisms · doi:10.3390/microorganisms7100437 · Cited by 17
“coli probiotics in reducing symptoms compared to a placebo or standard treatment [10], with a lack of placebo-control or blinding in some studies [10,11]; these articles have noted that the mechanisms within the gut by which E.”
BackgroundInfluentialMechanism of Lactobacillus reuteri Probiotic in Increasing Intestinal Mucosal Immune System
Guli, M. M., Winarsih, S., Barlıanto, W., Illiandri, O., & Sumarno, S. P. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.7447 · Cited by 13
“coli strain DSM 17252 G2, several species of Lactobacillus or VSL#3 [24].”
BackgroundMicrobiome and colorectal cancer: A review of the past, present, and future
Johns, M. S., & Petrelli, N. J. (2021) · Surgical Oncology · doi:10.1016/j.suronc.2021.101560 · Cited by 10
Escribano-Vázquez, U., Beimfohr, C., Bellet, D., Thomas, M., Zimmermann, K., Langella, P., & Cherbuy, C. (2020) · Microorganisms · doi:10.3390/microorganisms8040512 · Cited by 7
“These strains constitute the basis of at least three commercially available probiotic products, known under the commercial names Mutaflor®, Symbioflor2®, and Colinfant® [2,3].”
BackgroundSelf-citationJing, Q., Liu, H., & Wu, D. (2026) · Sensors & Diagnostics · doi:10.1039/d5sd00200a · Cited by 5
Potential of Escherichia coli Probiotics for Improved Health and Disease Management
Gattupalli, N., & Gattupalli, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100380 · Cited by 8
“coli strains, which brings about an increase in β-defensin-2 and reduces mast cell activation [19].”
BackgroundWang, C., Xing, J., Zhao, H., Chen, X., Niu, Z., Ma, X., Gui, Y., Qi, X., Shi, Y., Cheng, X., et al. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70076 · Cited by 6
Avgousti, K., Dushku, E., Spyropoulou, A., Kotzamanidis, C., Staikou, A. E., & Yiangou, M. (2025) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2025.105481 · Cited by 3
New antimicrobials to target gut and food pathogens
García-Gutiérrez, E. (2019) · UEA Digital Repository (University of East Anglia) · doi:10.13140/rg.2.2.20637.26082 · Cited by 4
Fields, B. D., Pascal, D. G., Rando, O. K., Huddleston, M., Ingram, K., Hopton, R., Grogg, M. W., Nelson, M., & Voigt, C. A. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00690 · Cited by 2
Diagnostic and Therapeutic Biotechnology
Raina, A., Villingiri, V., Jehan, S., & Qadir, S. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98554-7_10 · Cited by 3
Impact de souches commensales et probiotiques d'Escherichia coli sur la physiopathologie de l'hôte
Escribano-Vázquez, U. (2018) · theses.fr (ABES) · doi:10.70675/ae439ff5z4d13z4af2za21az2572e5749b15 · Cited by 1
PARAPROBİYOTİKLER VE POSTBİYOTİKLER: GIDA VE FARMAKOLOJİ UYGULAMALARI
Öztürk, B., Sulak, G., Eker, S., & Şengün, İ. Y. (2024) · GIDA / THE JOURNAL OF FOOD · doi:10.15237/gida.gd24054
Clinical Applications of Probiotics: A Comprehensive Review of Benefits and Challenges
Hassan, R. W. (2025) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1080
Corbín-Agustí, P., Arévalo-Lalanne, A., Álvarez, P., Enrique, M., Ramón, D., Peretó, J. G., & Tortajada, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.17.688048
Corbín-Agustí, P., Arévalo-Lalanne, A., Álvarez, P., Enrique, M., Ramón, D., Peretó, J. G., & Tortajada, M. (2026) · Microbial Biotechnology · doi:10.1111/1751-7915.70361 · Cited by 1
“…indispensable, powerful and robust computational tools in systems biology for elucidating microbial metabolism, predicting genotype–phenotype relationships, functional characteristics and optimizing industrial bioprocesses (Monk et al. 2013, 2016, 2017; Pearcy et al. 2021; Bernstein et al. 2023).”
Wasiewska, L. A., Kareem, L., Linares, A. G., Gunnigle, E., Risso, D., Laurie, I., van Sinderen, D., Clarke, G. A., & Schellekens, H. (2026) · Journal of Applied Microbiology · doi:10.1093/jambio/lxag124
Metadata
- Authors
- Beimfohr, C.
- Affiliations
- Vermicon (Germany) (DE)
- Corresponding author
- Beimfohr, Claudia
- ORCID
- Beimfohr, Claudia
- Venue
- International Journal of Bacteriology
- Publisher
- Wiley
- Published
- 2016-11-22
- Volume
- 2016
- Pages
- 1-10
- ISSN
- 2314-596X (ISSN-L)
- 2356-6957
- PMC
- PMC5138452
- OpenAlex
- W2555723171
- Cited by
- 30
- References
- 38
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 2
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International Journal of Bacteriology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Nursing › Nutrition and Dietetics › Infant Nutrition and Health
- Keywords
- probiotic Escherichia coli, probiotic activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.